Latest Medtech News
Medtronic plans to acquire Contego Medical, a privately held developer of carotid artery disease and peripheral thrombectomy devices. The deal is valued at $380 million with potential payments after closing, and is expected to close in the third quarter of Medtronic’s fiscal year, subject to customary conditions. It builds on an exclusive U.S. distribution agreement the two companies announced in January 2025.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The centerpiece is Contego’s recently FDA-approved Neuroguard IEP Direct System, which the companies describe as the first and only transcarotid artery revascularization system with integrated embolic protection in addition to flow reversal. Embolic debris released during carotid revascularization can contribute to procedural stroke risk, which is the problem the technology targets. In the prospective, multicenter PERFORMANCE III study, the company reports no strokes, neurological deaths, cranial nerve injuries or myocardial infarctions at 30 days. The deal also brings Excipio thrombectomy devices, which sit alongside Medtronic’s Liberant system in peripheral vascular disease.
For Medtronic, the acquisition turns a distribution partnership into ownership and widens its carotid portfolio. Medtronic Neurovascular’s Linnea Burman said the aim is technologies to “reduce stroke risk and advance patient care.” Medtronic expects the deal to be minimally dilutive to adjusted EPS in FY27 and FY28.
For the broader MedTech space, it adds to Medtronic’s run of targeted vascular and neuro acquisitions this year.



